한국 여성에서 호르몬 치료 중 진단된 유방암의 임상적 특성

Abstract

Objectives: This study was performed to evaluate clinical characteristics of breast cancers diagnosed in Korean women on hormone therapy (HT). Methods: In 95 patients who were diagnosed with primary breast cancer under current HT, information on clinical characteristics, HT, and breast cancer was derived from the medical records. Results: The mean age of menarche, menopause, and cancer diagnosis (±SD) was 15.6±1.6, 48.0±5.0, and 54.1±6.3 years, respectively. Thirty-eight percent of the patients received estrogen therapy and the 62% of the patients received combination therapy. The duration of HT was 41.3±34.9 months (range, 1∼151 months). Of note, 36.8% of the patients (35/95) received HT for ＜2 years. Forty percent of the patients (38/95) of patients had risk factor(s) for breast cancer. Ninety-three percent of the patients (88/95) underwent surgery as a primary treatment, and breast conservation surgery was performed in 38.6% of the patients (34/88). Ductal cancer was the histologic diagnosis in 94.4 %of the patients (85/90). Seventy-six percent of the patients (62/82) had at least 1 of the following good prognostic factors: stages 0 and I, 63.3% (50/79) tumor size ＜2 cm, 66.2% (49/74) estrogen receptor-positive tumors, 65.3% (47/72) and tumors without axillary lymph node involvement, 74.0% (57/77). Conclusion: This retrospective study suggests that breast cancer diagnosed in Korean women while taking HT have a favorable prognosis, possibly due to earlier detection and lower biologic aggressiveness.